DRG Fingertip insights
보험 플랜, 정책 제한, PBM, 의료 제공자 등 마켓 액세스 의사결정에 필요한 데이터와 인사이트를 제공합니다.
Report
2009년 9월 1일
Formulary Advantages in Osteoporosis: Rise and Fall of Access in the Wake of Fosamax Generics, Rebate and Contracting Efforts, and New Drug Launches
With 62 million cases of osteoporosis and osteopenia in the United States and a U.S. market of over $3.8 billion, few brands are competing for a very large appropriation of healthcare dollars. Major…
